ConductScience.org, home
Study of Pembrolizumab (MK-3475) as First-Line Monotherapy and Combination Therapy for Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (MK-3475-062/KEYNOTE-062)
API referenceFor AI assistants

Trial · NCT02494583

Adverse events1,375

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

1 to 20 of 1,375

Download this page as JSON
TypeEventOrgan systemGroupAffectedAt riskEvents
otherAnaemiaBlood and lymphatic system disordersPembrolizumab Monotherapy (Pembro Mono) First Course6125473
otherAnaemiaBlood and lymphatic system disordersPembrolizumab + SOC Chemotherapy (Pembro Combo)-First Course112250150
otherAnaemiaBlood and lymphatic system disordersPlacebo + SOC Chemotherapy (SOC)-First Course108244144
otherAnaemiaBlood and lymphatic system disordersPembrolizumab Monotherapy Second Course343
otherAnaemiaBlood and lymphatic system disordersPembrolizumab + SOC Chemotherapy-Second Course050
otherLeukopeniaBlood and lymphatic system disordersPembrolizumab Monotherapy (Pembro Mono) First Course02540
otherLeukopeniaBlood and lymphatic system disordersPembrolizumab + SOC Chemotherapy (Pembro Combo)-First Course2125052
otherLeukopeniaBlood and lymphatic system disordersPlacebo + SOC Chemotherapy (SOC)-First Course2624451
otherLeukopeniaBlood and lymphatic system disordersPembrolizumab Monotherapy Second Course040
otherLeukopeniaBlood and lymphatic system disordersPembrolizumab + SOC Chemotherapy-Second Course050
otherNeutropeniaBlood and lymphatic system disordersPembrolizumab Monotherapy (Pembro Mono) First Course12542
otherNeutropeniaBlood and lymphatic system disordersPembrolizumab + SOC Chemotherapy (Pembro Combo)-First Course95250201
otherNeutropeniaBlood and lymphatic system disordersPlacebo + SOC Chemotherapy (SOC)-First Course102244222
otherNeutropeniaBlood and lymphatic system disordersPembrolizumab Monotherapy Second Course040
otherNeutropeniaBlood and lymphatic system disordersPembrolizumab + SOC Chemotherapy-Second Course050
otherThrombocytopeniaBlood and lymphatic system disordersPembrolizumab Monotherapy (Pembro Mono) First Course22545
otherThrombocytopeniaBlood and lymphatic system disordersPembrolizumab + SOC Chemotherapy (Pembro Combo)-First Course2725038
otherThrombocytopeniaBlood and lymphatic system disordersPlacebo + SOC Chemotherapy (SOC)-First Course2624433
otherThrombocytopeniaBlood and lymphatic system disordersPembrolizumab Monotherapy Second Course040
otherThrombocytopeniaBlood and lymphatic system disordersPembrolizumab + SOC Chemotherapy-Second Course050

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Next page

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT02494583/events

API referenceFor AI assistants